LIPOLIPELLA PHARMACEUTICALS INC.

Nasdaq lipella.com


$ 0.41 $ -0.11 (-21.52 %)    

Monday, 09-Sep-2024 13:10:55 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 0.4023
$ 0.45
$ 0.38 x 450
-- x --
$ 0.40 - $ 0.45
$ 0.32 - $ 2.71
225,255
na
3.22M
$ -0.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lipella-pharmaceuticals-granted-us-patent-for-delivery-of-agents-using-metastable-liposomes-for-lead-drug-hemorrhagic-cystitis-cancer-painful-bladder-syndrome

https://patentcenter.uspto.gov/applications/17829960?application=

 lipella-pharmaceuticals-begins-phase-2a-trial-for-oral-lichen-planus-treatment

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," "we" or the "Company...

 lipella-pharmaceuticals-announces-128m-registered-direct-offering-of-2066000-shares-of-common-stock-or-pre-funded-warrants-in-lieu-thereof-at-a-purchase-price-of-062-per-share

Lipella Pharmaceuticals Inc. ("Lipella" or the "Company") (NASDAQ:LIPO), a clinical-stage biotechnology company...

 why-lipella-pharmaceutical-shares-are-soaring-today

Lipella Pharmaceuticals shares are trading higher Monday after the company announced the enrollment of the first patients in it...

Core News & Articles
Market-Moving News for July 29th
07/29/2024 12:22:29

LGVN:  49% | Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Di...

 lipella-pharmaceuticals-commences-phase-2a-trial-for-lp-310-in-oral-lichen-planus-enrolls-first-patients

Lipella's Phase 2a trial is a multi-center, dose-ranging study of LP-310, a proprietary liposomal-tacrolimus oral rinse for...

 lipella-reveals-receipt-of-fda-type-c-meeting-guidance-regarding-lp-10-liposomal-tacrolimus-clinical-program-plans-to-advance-lead-product-candidate-to-phase-2b

Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately...

 maxim-group-initiates-coverage-on-lipella-pharmaceuticals-with-buy-rating-announces-price-target-of-2

Maxim Group analyst Jason McCarthy initiates coverage on Lipella Pharmaceuticals (NASDAQ:LIPO) with a Buy rating and announc...

 lipella-pharmaceuticals-to-publish-abstract-detailing-preclinical-support-for-new-product-candidate-at-asco-2024

Lipella Pharmaceuticals Inc.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION